Clinical Trials Logo
  1. Home
  2. Scleritis
  3. NCT00415506

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

Scleritis Clinical Trial

Official title:
A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00415506
Study type Interventional
Source Oregon Health and Science University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date January 2007
Completion date March 2011
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00367692 - Study Evaluating PSI-697 in Patients With Scleritis Phase 1
Terminated NCT03660618 - LSFG-SKIN, Laser Speckle Flowgraphy N/A
Enrolling by invitation NCT01613963 - Causes of Visual Loss in Retinal Disease N/A
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT01835132 - Gevokizumab for Active Scleritis Phase 1/Phase 2
Completed NCT02764697 - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Phase 4
Completed NCT01517074 - Sirolimus Injections for Autoimmune Scleritis Phase 1/Phase 2
Recruiting NCT03465111 - A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis Phase 2
Completed NCT00075075 - Infliximab to Treat Non-Infectious Scleritis Phase 1
Recruiting NCT05200715 - AutoInflammatory Disease Alliance Registry (AIDA)
Terminated NCT00539370 - Human Samples and Data Repository
Active, not recruiting NCT03580343 - Tofacitinib for Inflammatory Eye Disease Phase 2